A number of pyrimidine acyclic nucleosides in which the acyclic moiety
is attached to the C-6 position rather than N-1 of the pyrimidine rin
g have been prepared. This was accomplished via treatment of lithiated
2,4-methoxy-5,6-dimethylpyrimidine, or, 2,4-dimethoxy-6-methylpyrimid
ine with 1,3-bis-(benzyloxy)-2-propanone, benzyl chloromethyl ether or
oxirane, respectively, to give the corresponding key intermediates zy
loxy-2-(benzyloxy)methyl-2-hydroxypropyl-2,4- dimethoxy-5-methylpyr
imidine (2a), y)methyl-2-hydroxypropyl-2,4-dimethoxypyrimidine (2b),
2-benzyloxyethyl)-2,4-dimethoxy-5-methylpyrimidine (3), and 4-dimetho
xy-6-(3-hydroxypropyl)-5-methylpyrimidine (4a). After acidic hydrolysi
s, followed by debenzylation with boron trichloride these key intermed
iates were converted to the target C-6 pyrimidine acyclic derivatives.
Compounds 6-8b, 11-13, 15, 16, 20, 22, 26, and 29-32 were evaluated f
or activity against herpes viruses and human immunodeficiency virus. N
one of the compounds were active against the viruses nor were they cyt
otoxic at the highest concentration tested.